A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer

O. Kaidar-Person; H.M. Dahn; A.M. Nichol; L.J. Boersma; D. de Ruysscher; I. Meattini; J.P. Pignol; C. Aristei; Y. Belkacemi; D. Benjamin; N. Bese; C.E. Coles; P. Franco; A.Y. Ho; S. Hol; R. Jagsi; A.M. Kirby; L. Marrazzo; G.N. Marta; M.S. Moran; H.D. Nissen; V. Strnad; Y. Zissiadis; P.M. Poortmans; B.V. Offersen

doi:10.1016/j.radonc.2021.09.012

A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer

O. Kaidar-Person^*, H.M. Dahn, A.M. Nichol, L.J. Boersma, D. de Ruysscher, I. Meattini, J.P. Pignol, C. Aristei, Y. Belkacemi, D. Benjamin, N. Bese, C.E. Coles, P. Franco, A.Y. Ho, S. Hol, R. Jagsi, A.M. Kirby, L. Marrazzo, G.N. Marta, M.S. MoranH.D. Nissen, V. Strnad, Y. Zissiadis, P.M. Poortmans, B.V. Offersen

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Web of Science)

Abstract

Bolus serves as a tissue equivalent material that shifts the 95-100% isodose line towards the skin and subcutaneous tissue. The need for bolus for all breast cancer patients planned for postmastectomy radiation therapy (PMRT) has been questioned. The work was initiated by the faculty of the European SocieTy for Radiotherapy & Oncology (ESTRO) breast cancer courses and represents a multidisciplinary international breast cancer expert collaboration to optimize PMRT. Due to the lack of randomised trials evaluating the benefits of bolus, we designed a stepwise project to evaluate the existing evidence about the use of bolus in the setting of PMRT to achieve an international consensus for the indications of bolus in PMRT, based on the Delphi method. (c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 164 (2021) 115-121

Original language	English
Pages (from-to)	115-121
Number of pages	7
Journal	Radiotherapy and Oncology
Volume	164
DOIs	https://doi.org/10.1016/j.radonc.2021.09.012
Publication status	Published - 1 Nov 2021

Keywords

Breast cancer
Mastectomy
Radiation therapy
PMRT
Bolus
Tissue compensator
SKIN-SPARING MASTECTOMY
CLINICAL-PRACTICE GUIDELINES
TARGET VOLUME DELINEATION
CARCINOMA-IN-SITU
LOCAL RECURRENCE
CHEST-WALL
REGIONAL RECURRENCE
PREDICTIVE FACTORS
AMERICAN-SOCIETY
RESIDUAL DISEASE

Access to Document

10.1016/j.radonc.2021.09.012

Cite this

Kaidar-Person, O., Dahn, H. M., Nichol, A. M., Boersma, L. J., de Ruysscher, D., Meattini, I., Pignol, J. P., Aristei, C., Belkacemi, Y., Benjamin, D., Bese, N., Coles, C. E., Franco, P., Ho, A. Y., Hol, S., Jagsi, R., Kirby, A. M., Marrazzo, L., Marta, G. N., ... Offersen, B. V. (2021). A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer. Radiotherapy and Oncology, 164, 115-121. https://doi.org/10.1016/j.radonc.2021.09.012

@article{20176fd660fb4e15b6c92cfe72eb5b89,

title = "A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer",

abstract = "Bolus serves as a tissue equivalent material that shifts the 95-100% isodose line towards the skin and subcutaneous tissue. The need for bolus for all breast cancer patients planned for postmastectomy radiation therapy (PMRT) has been questioned. The work was initiated by the faculty of the European SocieTy for Radiotherapy & Oncology (ESTRO) breast cancer courses and represents a multidisciplinary international breast cancer expert collaboration to optimize PMRT. Due to the lack of randomised trials evaluating the benefits of bolus, we designed a stepwise project to evaluate the existing evidence about the use of bolus in the setting of PMRT to achieve an international consensus for the indications of bolus in PMRT, based on the Delphi method. (c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 164 (2021) 115-121",

keywords = "Breast cancer, Mastectomy, Radiation therapy, PMRT, Bolus, Tissue compensator, SKIN-SPARING MASTECTOMY, CLINICAL-PRACTICE GUIDELINES, TARGET VOLUME DELINEATION, CARCINOMA-IN-SITU, LOCAL RECURRENCE, CHEST-WALL, REGIONAL RECURRENCE, PREDICTIVE FACTORS, AMERICAN-SOCIETY, RESIDUAL DISEASE",

author = "O. Kaidar-Person and H.M. Dahn and A.M. Nichol and L.J. Boersma and {de Ruysscher}, D. and I. Meattini and J.P. Pignol and C. Aristei and Y. Belkacemi and D. Benjamin and N. Bese and C.E. Coles and P. Franco and A.Y. Ho and S. Hol and R. Jagsi and A.M. Kirby and L. Marrazzo and G.N. Marta and M.S. Moran and H.D. Nissen and V. Strnad and Y. Zissiadis and P.M. Poortmans and B.V. Offersen",

year = "2021",

month = nov,

day = "1",

doi = "10.1016/j.radonc.2021.09.012",

language = "English",

volume = "164",

pages = "115--121",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

}

Kaidar-Person, O, Dahn, HM, Nichol, AM, Boersma, LJ , de Ruysscher, D, Meattini, I, Pignol, JP, Aristei, C, Belkacemi, Y, Benjamin, D, Bese, N, Coles, CE, Franco, P, Ho, AY, Hol, S, Jagsi, R, Kirby, AM, Marrazzo, L, Marta, GN, Moran, MS, Nissen, HD, Strnad, V, Zissiadis, Y, Poortmans, PM & Offersen, BV 2021, 'A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer', Radiotherapy and Oncology, vol. 164, pp. 115-121. https://doi.org/10.1016/j.radonc.2021.09.012

TY - JOUR

T1 - A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer

AU - Kaidar-Person, O.

AU - Dahn, H.M.

AU - Nichol, A.M.

AU - Boersma, L.J.

AU - de Ruysscher, D.

AU - Meattini, I.

AU - Pignol, J.P.

AU - Aristei, C.

AU - Belkacemi, Y.

AU - Benjamin, D.

AU - Bese, N.

AU - Coles, C.E.

AU - Franco, P.

AU - Ho, A.Y.

AU - Hol, S.

AU - Jagsi, R.

AU - Kirby, A.M.

AU - Marrazzo, L.

AU - Marta, G.N.

AU - Moran, M.S.

AU - Nissen, H.D.

AU - Strnad, V.

AU - Zissiadis, Y.

AU - Poortmans, P.M.

AU - Offersen, B.V.

PY - 2021/11/1

Y1 - 2021/11/1

N2 - Bolus serves as a tissue equivalent material that shifts the 95-100% isodose line towards the skin and subcutaneous tissue. The need for bolus for all breast cancer patients planned for postmastectomy radiation therapy (PMRT) has been questioned. The work was initiated by the faculty of the European SocieTy for Radiotherapy & Oncology (ESTRO) breast cancer courses and represents a multidisciplinary international breast cancer expert collaboration to optimize PMRT. Due to the lack of randomised trials evaluating the benefits of bolus, we designed a stepwise project to evaluate the existing evidence about the use of bolus in the setting of PMRT to achieve an international consensus for the indications of bolus in PMRT, based on the Delphi method. (c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 164 (2021) 115-121

AB - Bolus serves as a tissue equivalent material that shifts the 95-100% isodose line towards the skin and subcutaneous tissue. The need for bolus for all breast cancer patients planned for postmastectomy radiation therapy (PMRT) has been questioned. The work was initiated by the faculty of the European SocieTy for Radiotherapy & Oncology (ESTRO) breast cancer courses and represents a multidisciplinary international breast cancer expert collaboration to optimize PMRT. Due to the lack of randomised trials evaluating the benefits of bolus, we designed a stepwise project to evaluate the existing evidence about the use of bolus in the setting of PMRT to achieve an international consensus for the indications of bolus in PMRT, based on the Delphi method. (c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 164 (2021) 115-121

KW - Breast cancer

KW - Mastectomy

KW - Radiation therapy

KW - PMRT

KW - Bolus

KW - Tissue compensator

KW - SKIN-SPARING MASTECTOMY

KW - CLINICAL-PRACTICE GUIDELINES

KW - TARGET VOLUME DELINEATION

KW - CARCINOMA-IN-SITU

KW - LOCAL RECURRENCE

KW - CHEST-WALL

KW - REGIONAL RECURRENCE

KW - PREDICTIVE FACTORS

KW - AMERICAN-SOCIETY

KW - RESIDUAL DISEASE

U2 - 10.1016/j.radonc.2021.09.012

DO - 10.1016/j.radonc.2021.09.012

M3 - Article

C2 - 34563607

SN - 0167-8140

VL - 164

SP - 115

EP - 121

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

ER -